LIPOPHILICITY, AQUEOUS SOLUBILITY, AND DEGREE OF IONIZATION OF ATRACTYLODIN AND β-EUDESMOL, THE BIOACTIVE COMPOUNDS ISOLATED FROM ATRACTYLODES LANCEA
DOI:
https://doi.org/10.22159/ijpps.2021v13i6.41398Keywords:
Atractylodin, Beta-eudesmol, Physicochemical properties, Atractylodes lanceaAbstract
Objective: The study aimed to evaluate the critical physicochemical properties (lipophilicity, aqueous solubility, and degree of ionization) of atractylodin and β-eudesmol using in vitro testing.
Methods: Lipophilicity (Log P and Log D) was determined using the shake-flask method (n-octanol/water partition). Aqueous solubility was determined using kinetic solubility assay in media with pH ranging from 1.2 to 7.4. The degree of ionization (pKa) was determined using the potentiometric titration method.
Results: Log P and Log D values of 3.0-5.0 suggested moderate lipophilicity of both compounds. Both exhibited low aqueous solubility over the investigated pH range (0.08-0.93 and 1.97-32.48 μg/ml for atractylodin and β-eudesmol, respectively). Based on the pKa values of 9.63 (atractylodin) and 9.12 (b-eudesmol), both are classified as basidic compounds.
Conclusion: Atractylodin and β-eudesmol are classified as BCS class II drugs. The physicochemical parameters of both compounds obtained from the current study will be further applied for in silico prediction of their ADME (absorption, distribution, metabolism, and excretion) properties. In addition, PBPK modeling will be used for the prediction of optimal dose regimens of the capsule formulation of the standardized extract of Atractylodes lancea for first-in-human (FIH) and phase II studies in patients with cholangiocarcinoma.
Downloads
References
Khan SA, Thomas HC, Davidson BR, Taylor Robinson SD. Cholangiocarcinoma. Lancet 2005;366:1303-14.
National Cancer Institute. Cancer incidence in Thailand 2016. Bangkok: National Cancer Institute; 2018.
Forner A, Vidili G, Rengo M, Bujanda L, Ponz Sarvise M, Lamarca A. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int 2019;39 Suppl 1:98-107.
Xu K, Jiang JS, Feng ZM, Yang YN, Li L, Zang CX, et al. Bioactive sesquiterpenoid and polyacetylene glycosides from atractylodes lancea. J Nat Prod 2016;79:1567-75.
Jun X, Fu P, Lei Y, Cheng P. Pharmacological effects of medicinal components of Atractylodes lancea (Thunb.) DC. Chin Med 2018;13:59.
Plengsuriyakarn T, Viyanant V, Eursitthichai V, Picha P, Kupradinun P, Itharat A, et al. Anticancer activities against cholangiocarcinoma, toxicity and pharmacological activities of Thai medicinal plants in animal models. BMC Complement Altern Med 2012;12:23.
Plengsuriyakarn T, Karbwang J, Na-Bangchang K. Anticancer activity using positron emission tomography-computed tomography and pharmacokinetics of beta-eudesmol in human cholangiocarcinoma xenografted nude mouse model. Clin Exp Pharmacol Physiol 2015;42:293-304.
Martviset P, Chaijaroenkul W, Muhamad P, Na-Bangchang K. Bioactive constituents isolated from atractylodes lancea (Thunb.) DC. rhizome exhibit synergistic effect against cholangiocarcinoma cell. J Exp Pharmacol 2018;10:59-64.
Omar AI, Plengsuriyakarn T, Chittasupho C, Na-Bangchang K. Enhanced oral bioavailability and biodistribution of atractylodin encapsulated in PLGA nanoparticle in cholangiocarcinoma. Clin Exp Pharmacol Physiol 2021;48:318-28.
Na-Bangchang K, Kulma I, Plengsuriyakarn T, Tharavanij T, Kotawng K, Chemung A, et al. Phase I clinical trial to evaluate the safety and pharmacokinetics of capsule formulation of the standardized extract of Atractylodes lancea. J Trad Complement Med 2021. https://doi.org/10.1016/ j.jtcme.2021.02.002
US Food, Drug Administration. Guidance for industry: estimating the maximum safe starting dose in an adult healthy volunteer. US Food and Drug Administration, Rockville MD; 2005.
US Food, Drug Administration. Physiologically based pharmacokinetic analyses-format and content guidance for industry. Center for Drug Evaluation and Research, Silver Spring, MD; 2018.
Sager JE, Yu J, Ragueneau Majlessi I, Isoherranen N. Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches a systematic review of published models, applications, and model verification. Drug Metab Dispos 2015;43:1823-37.
Jones H, Rowland Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst Pharmacol 2013;2:e63.
Quignot N. Modeling bioavailability to organs protected by biological barriers. In Silico Pharmacol 2013;1:8.
Loftsson T. Physicochemical properties and pharmacokinetics. In: Loftsson T. editor. Essential Pharmacokinetics. Boston: Academic Press; 2015. p. 85-104.
Jain N, Verma A. Preformulation studies of pilocarpine hydrochloride as niosomal gels for ocular drug delivery. Asian J Pharm Clin Res 2020;13:149-55.
Sobolev VS. Determination of ionization constant (pKa) and octanol-water partition coefficient (Log P) of cyclopiazonic acid. J AOAC Int 2005;88:1367-70.
Maes E, Nikolaev V, Patek M. Kinetic solubility: measurement and data processing. Oro Valley: Analytical Department, Icagen-T Inc; 2017.
Alsenz J, Kansy M. High throughput solubility measurement in drug discovery and development. Adv Drug Delivery Rev 2007;59:546-67.
Anilkumar S, Namdeo J, Ojas S, Pravin P. Enhancement solubility and dissolution rate of paracetamol and ibuprofen by coamorphous particles using microwave technique. Asian J Pharm Clin Res 2019;12:155-62.
Hiendrawan S, Veriansyah B, Tjandrawinata RR. Solid-stateE properties and solubility studies of novel pharmaceutical cocrystal of itraconazol. Int J Appl Pharm 2018;10:97-104.
Volgyi G, Ruiz R, Box K, Comer J, Bosch E, Takacs Novak K. Potentiometric and spectrophotometric pKa determination of water-insoluble compounds: Validation study in a new cosolvent system. Anal Chem Acta 2007;583:418-28.
Avdeef A, Comer JEA, Thomson SJ. pH-metric log P. 3. Glass electrode calibration in methanol-water applied to pKa determination of water-insoluble substances. Anal Chem 1993;65:42-9.
Takacs Novak K, Box KJ, Avdeef A. Potentiometric pKa determination of water-insoluble compounds: validation study in methanol/water mixtures. Int J Pharm 1997;151:235-48.
Shargel L, Wu Pong S, Yu ABC. Chapter 10. Physiologic drug distribution and protein binding. Applied Biopharmaceutics andamp; Pharmacokinetics, 6e. New York, NY: The McGraw-Hill Companies; 2012.
Kwon Y. Handbook of essential pharmacokinetics, pharmacodynamics and drug metabolism for industrial scientists. New York: Kluwer; 2002.
Comer J, Tam K. Lipophilicity profiles: theory and measurement. In: van de Waterbeemd H, Folkers G, Guy R. editors. Pharmacokinetic optimization in drug research: Biological, physicochemical, and computational strategies. Weinheim: John Wiley and Sons; 2001. p. 275-304.
Valko K. Application of high-performance liquid chromatography-based measurements of lipophilicity to model biological distribution. J Chromatogr A 2004;1037:299-310.
Andres A, Roses M, Rafols C, Bosch E, Espinosa S, Segarra V, et al. Setup and validation of shake-flask procedures for the determination of partition coefficients (logD) from low drug amounts. Eur J Pharm Sci 2015;76:181-91.
Tetko I, Poda G, Ostermann C, Mannhold R. Accurate in silico log P predictions: one can't embrace the unembraceable. QSAR Com Sci 2009;28. https://doi.org/10.1002/qsar.200960003
ChemSpider. Cambridge: Royal Society of Chemistry; c2021. Available from: http://www.chemspider.com/Chemical-Structure.9054030.html. [Last accessed on 15 Feb 2021]
ChemSpider. Cambridge: Royal Society of Chemistry; c2021. Available from: http://www.chemspider.com/Chemical-Structure.83751.html. [Last accessed on 15 Feb 2021]
ChemSpider. Cambridge: Royal Society of Chemistry; c2021. Available from: http://www.chemspider.com/Chemical-Structure.389830.html. [Last accessed on 15 Feb 2021]
ChemSpider. Cambridge: Royal Society of Chemistry; c2021. Available from: http://www.chemspider.com/Chemical-Structure.391214.html. [Last accessed on 15 Feb 2021]
ChemSpider Cambridge: Royal Society of Chemistry; c2021. Available from: http://www.chemspider.com/Chemical-Structure.62060.html. [Last accessed on 15 Feb 2021]
ChemSpider. Cambridge: Royal Society of Chemistry; c2021. Available from: http://www.chemspider.com/Chemical-Structure.4478932.html. [Last accessed on 15 Feb 2021]
ChemSpider. Cambridge: Royal Society of Chemistry; c2021. Available from: http://www.chemspider.com/Chemical-Structure.82584.html. [Last accessed on 15 Feb 2021]
PubChem. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; c2004. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/beta-Eudesmol. [Last accessed on 15 Feb 2021]
PubChem. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; c2004. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Atractylodin. [Last accessed on 15 Feb 2021]
Siew A. Dissolution testing. Pharm Technol Euro 2016;40:56-64.
Dehring K, Workman H, Miller K, Mandagere A, Poole S. Automated robotic liquid handling/laser-based nephelometry system for high throughput measurement of kinetic aqueous solubility. J Pharm Biomed Anal 2004;36:447-56.
Saal C, Petereit A. Optimizing solubility: kinetic versus thermodynamic solubility temptations and risks. Eur J Pharm Sci 2012;47:589-95.
TGSC Information System. The Good Scents Company; c1980. Available from: http://www.thegoodscentscompany.com/ data/rw1539051.html. [Last accessed on 15 Feb 2021]
TGSC Information System. The Good Scents Company; c1980. Available from: http://www.thegoodscentscompany.com/ data/rw1054041.html. [Last accessed on 15 Feb 2021]
Rattanathada T, Plengsuriyakarn T, Asasujarit R, Cheoymang A, Karbwang J, Na-Bangchang K. Development of oral pharmaceutical formulation of standardized crude ethanolic extract of atractylodes lancea (Thunb) DC. J Chin Pharm Sci 2020;29:280-93.
Muhamad N, Plengsuriyakarn T, Chittasupho C, Na-Bangchang K. The potential of atractylodin-loaded PLGA nanoparticles as chemotherapeutic for cholangiocarcinoma. Asian Pac J Cancer Prev 2020;21:935-41.
Hou T, Wang J, Zhang W, Wang W, Xu X. Recent advances in computational prediction of drug absorption and permeability in drug discovery. Curr Med Chem 2006;13:2653-67.
Martell AE, Motekaitis RJ. Determination and use of stability constants; 1992.
FooDB. The metabolomics innovation centre; c2021. Available from: https://foodb.ca/compounds/FDB003839. [Last accessed on 15 Feb 2021].
ChemicalBook. ChemicalBook Inc; c2017. Available from: https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6135964.htm. [Last accessed on 15 Feb 2021]
Stocks M. Chapter 3-the small molecule drug discovery process–from target selection to candidate selection. In: Ganellin R, Roberts S, Jefferis R. editors. Introduction to Biological and Small Molecule Drug Research and Development. Oxford: Elsevier; 2013. p. 81-126.
World Health Organization. WHO expert committee on specifications for pharmaceutical preparations. Fortieth report. World Health Organ Tech Rep Ser 2006;937:1-461.
Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-20.
Published
How to Cite
Issue
Section
